APG-222

N/A

Report date: 2023/12/25 11:55:13

Base Information

Drug NameAPG-222
Drug Alias NameAPG-222APG222PR-012PR012
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTumor necrosis factor ligand superfamily member 4 inhibitorsInterleukin-13 inhibitors
TargetsTumor necrosis factor ligand superfamily member 4Interleukin-13
Therapy Area/IndicationsDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesApogee Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesParagon Therapeutics IncApogee Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A